Ribociclib trials for HER2-negative Breast Cancer

All Ribociclib trials · All HER2-negative Breast Cancer trials

Phase breakdown

Recruiting trials studying Ribociclib for HER2-negative Breast Cancer

• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
  NCT05452213 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 52 locations
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations

Common questions

How many trials study Ribociclib for HER2-negative Breast Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.